Capricor Therapeutics (NASDAQ: CAPR) saw its shares decline 8.0% on Friday, closing at $6.29, as investors reacted to the FDA's decision to postpone its review deadline for deramiocel, the company's lead candidate for Duchenne muscular dystrophy. The delay leaves the stock trading at a premium of only about $2.20 per share above its June cash balance, a modest cushion that underscores the uncertainty surrounding the drug's approval prospects.
The FDA's postponement, announced after market hours on August 14, pushed back the original August 22 target action date to allow for review of new 24-month data from the HOPE-3 trial. The company said the amendment would replace the previous deadline, but a revised date has not yet been disclosed. This development follows a 70% intraday surge in the stock on August 14 when news of the FDA's willingness to review additional data first emerged.
Capricor's cash position provides some support. As of June 30, the company held $237.9 million in cash and marketable securities, with 58.1 million shares outstanding, translating to approximately $4.09 per share. Friday's close of $6.29 implies a market capitalization of roughly $365 million, leaving an equity premium of about $127.6 million, or $2.20 per share, attributable to deramiocel and the company's platform technology.
The cash cushion is shrinking, however. During the first half of 2026, Capricor's cash balance fell by $80.2 million, driven by a 55% increase in second-quarter operating expenses to $42.9 million and a net loss of $40.7 million, up from $25.9 million in the same period last year. At the current burn rate, the company's cash would cover about 19 months, though management has stated it has sufficient resources for at least 12 months.
The FDA's decision to review additional data comes after an advisory committee voted 9-3 against finding substantial evidence of effectiveness for deramiocel in treating Duchenne cardiomyopathy on July 29. That vote was nonbinding, and the committee did not address the HOPE-3 upper-limb primary endpoint, which met statistical significance (PUL 2.0, p=0.029). A prespecified cardiomyopathy subgroup also showed a supportive result (p=0.02), though the full-trial left ventricular ejection fraction (LVEF) difference was not conventionally significant.
Analyst sentiment remains deeply divided. The average price target stands at $10.50, but the median is just $6, reflecting a wide range from $2 (Piper Sandler) to $28 (Cantor Fitzgerald). This divergence highlights the binary nature of the regulatory outcome: a favorable decision could send shares soaring, while a rejection or further delay could erode much of the current premium.
Capricor has not provided a new timeline for the FDA's decision. A Roth Capital analyst suggested that a major amendment could add roughly three months to the review process, but that remains an estimate. The company has slowed commercial hiring and paused programs unrelated to deramiocel pending regulatory clarity, signaling a focus on preserving cash.
CEO Linda Marbán expressed confidence in the path forward, stating, "We continue to believe there is a path to approval for Deramiocel." However, the company faces significant risks, including the possibility of rejection, additional data requests, or a narrowed label, all of which could impact the stock's valuation.
Investors will be watching for updates on the FDA's revised action date and any further regulatory communications. The delayed decision removes the immediate binary event but does not resolve the underlying evidence dispute, leaving Capricor's shares in a precarious position as the company awaits clarity.
